Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797572 | 0.86 | TP53 (0.53) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL6183972 | 0.82 | ALDH1A1 (0.52) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL13529198 | 0.80 | MGLL (0.59) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL12325529 | 0.80 | MGLL (0.59) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL3796516 | 0.79 | MGLL (0.65) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL3787405 | 0.79 | MGLL (0.58) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL27543872 | 0.78 | MGLL (0.59) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL11694836 | 0.78 | TP53 (0.57) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL7401754 | 0.77 | MAPT (0.45) | TP53MAPTNPC1ALDH1A1TSHR | |
| SCHEMBL7401757 | 0.77 | MAPT (0.45) | TP53MAPTNPC1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | TP53 471/4885MAPT 4757/4885NPC1 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.